Literature DB >> 22158744

Experimental cerebral malaria develops independently of caspase recruitment domain-containing protein 9 signaling.

Julius Clemence R Hafalla1, Jan Burgold, Anca Dorhoi, Olaf Gross, Jürgen Ruland, Stefan H E Kaufmann, Kai Matuschewski.   

Abstract

The outcome of infection depends on multiple layers of immune regulation, with innate immunity playing a decisive role in shaping protection or pathogenic sequelae of acquired immunity. The contribution of pattern recognition receptors and adaptor molecules in immunity to malaria remains poorly understood. Here, we interrogate the role of the caspase recruitment domain-containing protein 9 (CARD9) signaling pathway in the development of experimental cerebral malaria (ECM) using the murine Plasmodium berghei ANKA infection model. CARD9 expression was upregulated in the brains of infected wild-type (WT) mice, suggesting a potential role for this pathway in ECM pathogenesis. However, P. berghei ANKA-infected Card9(-/-) mice succumbed to neurological signs and presented with disrupted blood-brain barriers similar to WT mice. Furthermore, consistent with the immunological features associated with ECM in WT mice, Card9(-/-) mice revealed (i) elevated levels of proinflammatory responses, (ii) high frequencies of activated T cells, and (iii) CD8(+) T cell arrest in the cerebral microvasculature. We conclude that ECM develops independently of the CARD9 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158744      PMCID: PMC3294660          DOI: 10.1128/IAI.06033-11

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity.

Authors:  Olaf Gross; Andreas Gewies; Katrin Finger; Martin Schäfer; Tim Sparwasser; Christian Peschel; Irmgard Förster; Jürgen Ruland
Journal:  Nature       Date:  2006-07-12       Impact factor: 49.962

2.  Caspase-1 activation of interleukin-1β (IL-1β) and IL-18 is dispensable for induction of experimental cerebral malaria.

Authors:  Maximilian Kordes; Kai Matuschewski; Julius Clemence R Hafalla
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  Isolation of brain parenchymal lymphocytes for flow cytometric analysis. Application to acute viral encephalitis.

Authors:  D N Irani; D E Griffin
Journal:  J Immunol Methods       Date:  1991-06-03       Impact factor: 2.303

4.  The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens.

Authors:  Yen-Michael S Hsu; Yongliang Zhang; Yun You; Donghai Wang; Hongxiu Li; Omar Duramad; Xiao-Feng Qin; Chen Dong; Xin Lin
Journal:  Nat Immunol       Date:  2006-12-24       Impact factor: 25.606

5.  Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor.

Authors:  G E Grau; H Heremans; P F Piguet; P Pointaire; P H Lambert; A Billiau; P Vassalli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

6.  Involvement of IFN-gamma receptor-medicated signaling in pathology and anti-malarial immunity induced by Plasmodium berghei infection.

Authors:  V Amani; A M Vigário; E Belnoue; M Marussig; L Fonseca; D Mazier; L Rénia
Journal:  Eur J Immunol       Date:  2000-06       Impact factor: 5.532

7.  Pathological role of Toll-like receptor signaling in cerebral malaria.

Authors:  Cevayir Coban; Ken J Ishii; Satoshi Uematsu; Nobuko Arisue; Shintaro Sato; Masahiro Yamamoto; Taro Kawai; Osamu Takeuchi; Hajime Hisaeda; Toshihiro Horii; Shizuo Akira
Journal:  Int Immunol       Date:  2006-11-29       Impact factor: 4.823

Review 8.  Experimental models of cerebral malaria.

Authors:  C Engwerda; E Belnoue; A C Grüner; L Rénia
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

9.  Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity.

Authors:  Gowdahalli Krishnegowda; Adeline M Hajjar; Jianzhong Zhu; Erika J Douglass; Satoshi Uematsu; Shizuo Akira; Amina S Woods; D Channe Gowda
Journal:  J Biol Chem       Date:  2004-12-28       Impact factor: 5.157

10.  On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria.

Authors:  Elodie Belnoue; Michèle Kayibanda; Ana M Vigario; Jean-Christophe Deschemin; Nico van Rooijen; Mireille Viguier; Georges Snounou; Laurent Rénia
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

View more
  5 in total

1.  Involvement of Nod2 in the innate immune response elicited by malarial pigment hemozoin.

Authors:  Yolanda Corbett; Silvia Parapini; Sarah D'Alessandro; Diletta Scaccabarozzi; Bruno C Rocha; Timothy J Egan; Aneesa Omar; Laura Galastri; Katherine A Fitzgerald; Douglas T Golenbock; Donatella Taramelli; Nicoletta Basilico
Journal:  Microbes Infect       Date:  2014-11-21       Impact factor: 2.700

2.  Plasmodium berghei sporozoites acquire virulence and immunogenicity during mosquito hemocoel transit.

Authors:  Yuko Sato; Georgina N Montagna; Kai Matuschewski
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

Review 3.  Signalling C-type lectin receptors, microbial recognition and immunity.

Authors:  J Claire Hoving; Gillian J Wilson; Gordon D Brown
Journal:  Cell Microbiol       Date:  2014-01-10       Impact factor: 3.715

Review 4.  Interferons and interferon regulatory factors in malaria.

Authors:  Sin Yee Gun; Carla Claser; Kevin Shyong Wei Tan; Laurent Rénia
Journal:  Mediators Inflamm       Date:  2014-07-15       Impact factor: 4.711

5.  Host Resistance to Plasmodium-Induced Acute Immune Pathology Is Regulated by Interleukin-10 Receptor Signaling.

Authors:  Carla Claser; J Brian De Souza; Samuel G Thorburn; Georges Emile Grau; Eleanor M Riley; Laurent Rénia; Julius C R Hafalla
Journal:  Infect Immun       Date:  2017-05-23       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.